Open Philanthropy made a seed investment of $3,000,000 to support further development of a pan-viral immunomodulator.
Open Philanthropy invested $3,000,000 in the newly formed company Eiger InnoTherapeutics, founded by Professor Jeffrey S. Glenn from Stanford University. Eiger InnoTherepautics acquired the rights to two drugs, lonafarnib and pegylated interferon lambda. The company will develop Lonafarnib for use against hepatitis D, for which there is no FDA-approved drug for HDV, the worst form of human viral hepatitis.
Interferon Lambda has demonstrated broad-spectrum antiviral activity. The company will seek to work in collaboration with the FDA and other regulatory authorities and collaborators to address multiple important high unmet needs that might be addressed using pegylated interferon lambda.